Cancer Communications (Mar 2025)
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update
- Feng Wang,
- Gong Chen,
- Zhen Zhang,
- Ying Yuan,
- Yi Wang,
- Yuan‐Hong Gao,
- Weiqi Sheng,
- Zixian Wang,
- Xinxiang Li,
- Xianglin Yuan,
- Sanjun Cai,
- Li Ren,
- Yunpeng Liu,
- Jianmin Xu,
- Yanqiao Zhang,
- Houjie Liang,
- Xicheng Wang,
- Aiping Zhou,
- Jianming Ying,
- Guichao Li,
- Muyan Cai,
- Gang Ji,
- Taiyuan Li,
- Jingyu Wang,
- Hanguang Hu,
- Kejun Nan,
- Liuhong Wang,
- Suzhan Zhang,
- Jin Li,
- Rui‐Hua Xu
Affiliations
- Feng Wang
- Department of Medical Oncology Sun Yat‐sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences Guangzhou Guangdong P. R. China
- Gong Chen
- Department of Colorectal Surgery Sun Yat‐sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Guangzhou Guangdong P. R. China
- Zhen Zhang
- Department of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai P. R. China
- Ying Yuan
- Department of Medical Oncology The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang P. R. China
- Yi Wang
- Department of Radiology Peking University People's Hospital Beijing P. R. China
- Yuan‐Hong Gao
- Department of Radiation Oncology Sun Yat‐sen University Cancer Centre, The State Key Laboratory of Oncology in South China Guangzhou Guangdong P. R. China
- Weiqi Sheng
- Department of Pathology Fudan University Shanghai Cancer Center Shanghai P. R. China
- Zixian Wang
- Department of Medical Oncology Sun Yat‐sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences Guangzhou Guangdong P. R. China
- Xinxiang Li
- Department of Colorectal Surgery Fudan University Shanghai Cancer Center Shanghai P. R. China
- Xianglin Yuan
- Department of Oncology Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei P. R. China
- Sanjun Cai
- Department of Colorectal Surgery Fudan University Shanghai Cancer Center Shanghai P. R. China
- Li Ren
- Department of General Surgery Zhongshan Hospital Fudan University Shanghai P. R. China
- Yunpeng Liu
- Department of Medical Oncology The First Hospital of China Medical University Shenyang Liaoning P. R. China
- Jianmin Xu
- Department of General Surgery Zhongshan Hospital Fudan University Shanghai P. R. China
- Yanqiao Zhang
- Department of Oncology Harbin Medical University Cancer Hospital Harbin Heilongjiang P. R. China
- Houjie Liang
- Department of Oncology Southwest Hospital Third Military Medical University (Army Medical University) Chongqing P. R. China
- Xicheng Wang
- Department of Gastrointestinal Oncology Cancer Medical Center, Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China
- Aiping Zhou
- Department of Medical Oncology Chinese Academy of Medical Sciences and Peking Union Medical College Beijing P. R. China
- Jianming Ying
- Department of Pathology Chinese Academy of Medical Sciences and Peking Union Medical College Beijing P. R. China
- Guichao Li
- Department of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai P. R. China
- Muyan Cai
- Department of Pathology Sun Yat‐sen University Cancer Center, The State Key Laboratory of Oncology in South China Guangzhou Guangdong P. R. China
- Gang Ji
- Department of Gastrointestinal Surgery Xijing Hospital Air Force Military Medical University Xi'an Shaanxi P. R. China
- Taiyuan Li
- Department of General Surgery The First Affiliated Hospital of Nanchang University Nanchang Jiangxi P. R. China
- Jingyu Wang
- Department of Radiology The First Hospital of Jilin University Changchun Jilin P. R. China
- Hanguang Hu
- Department of Medical Oncology The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang P. R. China
- Kejun Nan
- Department of Medical Oncology The First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi P. R. China
- Liuhong Wang
- Department of Radiology Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang P. R. China
- Suzhan Zhang
- Department of Colorectal Surgery The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang P. R. China
- Jin Li
- Department of Medical Oncology Shanghai GoBroad Cancer Hospital China Pharmaceutical University Shanghai P. R. China
- Rui‐Hua Xu
- Department of Medical Oncology Sun Yat‐sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat‐sen University, Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences Guangzhou Guangdong P. R. China
- DOI
- https://doi.org/10.1002/cac2.12639
- Journal volume & issue
-
Vol. 45,
no. 3
pp. 332 – 379
Abstract
Abstract The 2024 updates of the Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for the diagnosis and treatment of colorectal cancer emphasize standardizing cancer treatment in China, highlighting the latest advancements in evidence‐based medicine, healthcare resource access, and precision medicine in oncology. These updates address disparities in epidemiological trends, clinicopathological characteristics, tumor biology, treatment approaches, and drug selection for colorectal cancer patients across diverse regions and backgrounds. Key revisions include adjustments to evidence levels for intensive treatment strategies, updates to regimens for deficient mismatch repair (dMMR)/ microsatellite instability‐high (MSI‐H) patients, proficient mismatch repair (pMMR)/ microsatellite stability (MSS) patients who have failed standard therapies, and rectal cancer patients with low recurrence risk. Additionally, recommendations for digital rectal examination and DNA polymerase epsilon (POLE)/ DNA polymerase delta 1 (POLD1) gene mutation testing have been strengthened. The 2024 CSCO Guidelines are based on both Chinese and international clinical research, as well as expert consensus, ensuring their relevance and applicability in clinical practice, while maintaining a commitment to scientific rigor, impartiality, and timely updates.
Keywords
- adjuvant
- chemotherapy
- Chinese Society of Clinical Oncology (CSCO)
- colorectal cancer
- diagnosis
- immunotherapy
